MVAF 2018 Provisional Programme
Wednesday 4th May 2018
SESSION 1: PLENARY SESSION I
‘Defined adjuvants for cancer vaccines’
Ferry A. Ossendorp ( Leiden University Medical Center, Leiden, The Netherlands)
" TranslationalVaccinology: A myth"?
GeertvandenBossche(Belgium)
Coffee Break
SESSION 2: PLENARY SESSION II
‘Distinct adjuvants requirement for induction of T versus B cell responses’
Martin Bachmann (University of Basel, Basel, Switzerland/University of Oxford, Oxford, UK)
‘Host directed therapy by immunostimulants and novel compounds’
Tom H.M. Ottenhoff
( Leiden University Medical Center, Leiden, The Netherlands)
‘Vaccine formulation a matter for accomplishment’
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Lunch Break
SESSION 3: PLEANRY SESSION III
'Anti-tumour vaccines: An Update’
KeesMelief(ISA-Pharmaceuticals BV, Leiden, The Netherlands)
‘Immune-engineering antigens for better vaccine design’
Lenny Moise(EpiVax Inc., Providence, Rhode Island, USA)
‘Opportunities and challenges in characterizing the safety of new adjuvants’
Thomas Verstraeten, Marc Baayand KaatjeBollaerts
(P95 Epidemiology and Pharmacovigilance Services, Leuven, Belgium)
Tea Break
SESSION 4: VIRUS TOPICS
‘A virosomal RSV vaccine containing the 3D-PHAD® adjuvant based on thermostable virus’
ToonStegmann(Mymetics BV, Leiden, The Netherlands)
’Mucosal immunity may be the missing link to improve the poor and variable efficacy of flu vaccines: Protection by intranasal vaccination withNanostatR-Pandemic flu (rH5) in ferrets’
Ali Fattom, Doug Smith andViraBitko( NanoBio Corp. Ann Arbor, Michigan, USA)
‘OW-14: A new adjuvant for swine influenza virus and Mycoplasmahyopneumoniae vaccines’
Jishu Shi, A. Galliher-Beckley, L.K. Pappan, Q. Zhong, S. McVey and S.S. Dritz
(College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA)
Thursday 3rd May 2018
SESSION 5: PLENARY SESSION IV
‘TB Vaccines overview’
Tom H.M. Ottenhoff ( Leiden University Medical Center, Leiden, The Netherlands)
‘Rational design of next generation TLR4 adjuvants’
Darrick Carter (IDRI, Seattle, Washington, USA)
‘NHP models for vaccines, adjuvants and delivery systems’
Edmond J. Remarque
(Biomedical Primate Research Centre, Rijswijk, The Netherlands)
Coffee Break
SESSION 6: ADJUVANTS I
‘The functional effects of the Amplivant adjuvant (TLR1/2 ligand)’
KeesMelief(ISA-Pharmaceuticals BV, Leiden, The Netherlands)
‘Advanced kinetic analysis and long-term predictions for the oil-in-water emulsion-based adjuvant formulation"
Sandrine Cigarini (Sanofi Pasteur, Marcy l’Etoile, France)
‘Evaluation of TLR-4-agonist and cAMP-based (dmLT) adjuvants in combination for delivery of anti-enterotoxigenicE. coli vaccine candidates by the intradermal or intramuscular routes’
Milton Maciel Jr.1,2, Zoltan Beck2,3, Stefanie Trop1,2, Garry R. Matyas3, Steven Poole1,2, Aaron Kim1,2, Beth Ward1,2, Zuzana Villar1,2, Carl R. Alving3, Michael G. Prouty1
1Naval Medical Research Center, Silver Spring, MD, USA. 2Henry M. Jackson Foundation, Bethesda, Maryland, USA. 3Walter Reed Army Institute of Research, Silver Spring, Maryland, USA)
Lunch Break
SESSION 7: ADJUVANTS II
‘A new generation of a versatile adjuvant A that is delivering, targeting and immune modulating’
BrorMorein, Caroline Fossum and SaidehBerenjian
(Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden)
‘Adjuvant properties of the TLR7/8 agonist 3M-052’
Mark Tomai(3M Company, St Paul, Minnesota, USA)
‘Adjuvant safety: role of T cell derived GPIb protein in production of pro-inflammatory molecules PGE2 and IL-1 in primary human monocytes activated with muramyldipeptide adjuvant’
Marina Zaitseva, Fengjie Liu, Tatiana Romantseva, Wells Wu, Rong-Fong Shen and Hana Golding
(Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA)
Tea Break
SESSION 8: GENERAL
‘Ancerpipeline update’
Guilhem Richard,Gad Berdugo and Annie DeGroot(EPIVAX Inc., Providence, Rhode Island, USA)
Title to be confirmed
Michelle Chan (IDRI, Seattle, Washington, USA)
‘US Army liposomal formulations’
SheetijDutta (Military Malaria Research Program, Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring Maryland, USA)
Friday 4th May 2018
SESSION 9: GENERAL SESSION
‘Restoring T-cell homeostasis in atherosclerosis using liposomal vaccine formulations’
Bram Slutter(LACDR, University of Leiden, Leiden, The Netherlands)
‘Title to be confirmed’
Jean Haensler (Sanofi Pasteur, Marcy l’Etoile, France)
‘Targeted delivery through formulation design: CAF24, a novel adjuvant for CTL induction’
Signe Tandrup Schmidt (Statens Serum Institut, Copenhagen, Denmark)
Coffee Break
SESSION 10:
Title to be confirmed
Ryan Kramer (IDRI, Seattle, Washington, USA)
‘Development of a thermostable DNA vaccine formulation for challenging clinical environments’
Stephanie Ramos (Inovio Inc., Blue Bell Pennsylvania, USA)
‘Title to be confirmed
Arnaud Didierlaurent(GSK Vaccines, Rixensart, Belgium)
Lunch Break
SESSION 11: GENERAL SESSION
‘Title to be confirmed’
Maria Lazaro(SEPPIC, Paris, France)
‘Title to be confirmed’
Marie Garinot (Sanofi Pasteur, Marcy l’Etoile, France)
‘Identification of biomarkers that evaluate and screen new adjuvant candidates for safe and efficient influenza vaccines’
Takuo Mizukami(National Institute of Infectious Diseases, Tokyo, Japan)